Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-blind, Randomized, Multicenter, Multinational, Active-controlled, Non-inferiority Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

NCT07054099 is registered in ClinicalTrials.gov with GC Biopharma Corp as lead sponsor.

NCT NCT07054099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07054099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-blind, Randomized, Multicenter, Multinational, Active-controlled, Non-inferiority Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
Lead sponsor
GC Biopharma Corp
Phase
Phase 3
Overall status
Recruiting
Start date
March 17, 2026
Completion date
July 31, 2036
Enrollment
474 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chickenpox vaccine, varicella (chickenpox)